A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

NCT04746040 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence
Asthma

Interventions

DRUG: Test
DRUG: Reference

Sponsor

Respirent Pharmaceuticals Co Ltd.

Collaborators

[object Object]